Clinical application of whole exome sequencing in monogenic hereditary disorders in critically ill newborns.
- Author:
Zhi-Ye QI
1
;
Jiang DUAN
;
Xiang-Ying HE
;
Qing-Hua ZHONG
;
Cai-Ying ZHANG
;
Yun-Bo XIE
;
Kun LIANG
Author Information
1. Department of Pediatrics, First Affiliated Hospital of Kunming Medical University, Kunming 650032, China. Kunliang_cn@126.com.
- Publication Type:Journal Article
- MeSH:
Critical Illness;
Exome;
Female;
Humans;
Infant, Newborn;
Male;
Mutation;
Phenotype;
Whole Exome Sequencing
- From:
Chinese Journal of Contemporary Pediatrics
2019;21(7):640-643
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the value and significance of the clinical application of whole exome sequencing (WES) in monogenic hereditary disorders in critically ill newborns.
METHODS:The critically ill newborns in the neonatal intensive care unit with suspected hereditary diseases or unclear clinical diagnosis from June 2016 to December 2018 were enrolled. The whole blood samples from both newborns and parents were collected for WES. The detected genetic mutations were classified, the mutations associated with clinical phenotypes were searched for, and Sanger sequencing was performed to verify the mutations.
RESULTS:A total of 45 newborns were enrolled, including 22 males and 23 females, and the median age of onset was 2.0 days. Of the 45 newborns, 12 (27%) were confirmed with monogenic hereditary disorders by molecular diagnostics, and the median age at diagnosis was 31.5 days. Of the 12 newborns with monogenic hereditary disorders, 5 (42%) were partially associated with clinical phenotypes but confirmed with monogenic hereditary disorders by additional information supplement and analysis. The improvement rate of newborns with monogenic hereditary disorders was 67% (8/12) after treatment.
CONCLUSIONS:WES technology is a powerful tool for finding genetic mutations in monogenic hereditary disorders in critically ill newborns and can play a crucial role in clinical decision-making. However, a comprehensive interpretation of sequence data requires physicians to take the clinical phenotypes and the results of WES into consideration simultaneously.
